Log in

Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Vertex PharmaceuticalsBayerZoetisRegeneron Pharmaceuticals
Price Information
Current Price$207.01$11.98$161.19$555.79
52 Week RangeBuyHoldBuyBuy
Beat the Market™ Rank
Overall Score2.
Analysis Score4.
Community Score3.
Dividend Score0.
Ownership Score1.
Earnings & Valuation Score1.
Analyst Ratings
Consensus RecommendationBuyHoldBuyBuy
Consensus Price Target$293.75N/A$156.15$622.13
% Upside from Price Target41.90% upsideN/A-3.12% downside11.94% upside
Trade Information
Market Cap$53.92 billion$44.69 billion$76.59 billion$59.13 billion
Average Volume1,830,510630,7752,082,0231,138,742
Sales & Book Value
Annual Revenue$4.16 billion$48.23 billion$6.26 billion$7.86 billion
Price / Sales12.950.9312.237.52
Cashflow$4.47 per share$3.33 per share$4.58 per share$23.08 per share
Price / Cash46.273.6035.1724.08
Book Value$23.66 per share$14.27 per share$5.69 per share$100.56 per share
Price / Book8.750.8428.335.53
Net Income$1.18 billion$4.58 billion$1.50 billion$2.12 billion
Trailing P/E Ratio26.14N/A47.8321.52
Forward P/E Ratio22.285.6839.1216.91
P/E Growth1.251.114.351.80
Net Margins38.51%-12.80%25.50%37.30%
Return on Equity (ROE)28.55%14.64%63.89%26.71%
Return on Assets (ROA)20.68%5.16%14.99%19.39%
Annual PayoutN/A$0.53$0.80N/A
Dividend YieldN/A4.42%0.50%N/A
Three-Year Dividend GrowthN/AN/AN/AN/A
Payout RatioN/A29.94%21.98%N/A
Years of Consecutive Dividend GrowthN/AN/A1 YearsN/A
Debt-to-Equity Ratio0.07%0.95%2.41%0.08%
Current Ratio3.72%0.90%3.47%2.12%
Quick Ratio3.60%0.62%2.60%1.68%
Ownership Information
Institutional Ownership Percentage92.17%0.12%92.50%85.89%
Insider Ownership Percentage0.70%N/A0.17%11.84%
Shares Outstanding260.47 million3.73 billion475.15 million106.39 million
Next Earnings DateN/A11/4/2020 (Estimated)11/5/2020 (Confirmed)11/5/2020 (Confirmed)
OptionableOptionableNot OptionableOptionableOptionable

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.